PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

no persons are required to respond to a collection of information unless it contains a valid OMB control number. uction Act of PADEMA Substitute for form 1449/P

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

AUG 1 1 2004

(Use as many sheets as necessary)

Complete if Known Application Number 09/831,047 Filing Date May 3, 2001 First Named Inventor Blaszczyk-Thurin Art Unit 1653 Examiner Name S. Snedden			
	Application Number	09/831,047	
	Filing Date	May 3, 2001	
	First Named Inventor		
	Art Unit		
	Examiner Name	S. Snedden	
	Attorney Docket Number	WST93AUSA	

Sheet	11	of 4		Attorney Docket Number VVS 193	AUSA
SHEEL	<u> </u>		A DATENIA	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ^{2 (# known)}	<u> </u>		- I garden specie
55	AF	^{US-} 2003/0017497-A1	01-23-2003	Keiber-Emmons et al.	
		US-			
	<u> </u>	US-			
		US-			
	 	US-			
		US-			
	<u> </u>	US-			
		US-	 		
		US-			
		US-			
		US-			
		US-			
		US-			
	L				

			N PATENT DOCU	MENTS	Pages, Columns, Lines,	Τ
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Where Relevant Passages Or Relevant Figures Appear	T⁵
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if knawn)	MIM-DD-1111			_
						┡
						

Date Examiner Considered Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For USPTO Patent Documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the This collection of information is required by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, USPTO time will vary depending upon the individual case. Any comments including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

AUG 1 1 2004

PTO/SB/08B (08-03)
Approved for use through 7/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Inder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

				Complete if Known
e for form 1	L449B/PTO		Application Number	09/831,047
ORMA	TION	DISCLOSURE	Filing Date	May 3, 2001
			First Named Inventor	Blaszczyk-Thurin
			Group Art Unit	1653
(lise as ma	nv sheets a	s necessary)	Examiner Name	S. Snedden
2		4	Attorney Docket Number	WST93AUSA
	ORMA ATEME	TEMENT BY	ORMATION DISCLOSURE ATEMENT BY APPLICANT	ORMATION DISCLOSURE Filing Date First Named Inventor Group Art Unit (Use as many sheets as necessary) Examiner Name

		NONPATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
55	BBZ	BECHTEL et al., "Conformational analysis of the tumor-associated carbohydrate antigen 19-9 and its Lea blood group antigen component as related to the specificity of monoclonal antibody CO19-9", J. Biol. Chem. February 5, 1990 265(4):2028-2037	
	CR	BLASZCZYK et al., "Characterization of gastrointestinal tumor-associated carcinoembryonic antigen-related antigens defined by monoclonal antibodies", Cancer	
	CS	BLASZCZYK et al., "Characterization of Lewis antigens in normal colon and gastrointestinal adenocarcinomas", <i>Proc. Natl. Acad. Sci. USA</i> June 1985 82(11):3552-3556	
	CT	BLASZCZYK et al., "Lewis blood group antigens defined by monoclonal anti-colon carcinoma antibodies" Arch. Biochem. Biophys. August 15, 1984 233(1):161-168	
	CU	BLASZCZYK-THURIN et al., "Biosynthetic pathways for the Leb and Y glycolipids in the gastric carcinoma cell line KATO III as analyzed by a novel assay", Biochem. Biophys. Res. Commun. February 29, 1988 151(1):100-108	
	CV	BLASZCZYK-THURIN et al., "Y and blood group B type 2 glycolipid antigens accumulate in a human gastric carcinoma cell line as detected by monoclonal antibody. Isolation and characterization by mass spectrometry and NMR spectroscopy", J. Biol. Chem. January 5, 1987 262(1):372-379	
	CW	FUKUSHI et al., "Location and distribution of difucoganglioside (VI3NeuAcV3III3Fuc2nLc6) in normal and tumor tissues defined by its monoclonal antibody FH6". Cancer Res. August 1985 45(8):3711-3717	
55	CX	GENG et al., "Lectin domain peptides from selectins interact with both cell surface ligands and Ca2+ ions, J. Hiol. Chem. October 5, 1992 267(28):19846-19853	

			∕	/ <u></u>
Examiner Signature		Date	/2/	n c/
Examiner digitation	100	Considered //	u	
		1		

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

AUG 1 1 2004 W

PTO/SB/08B (08-03)
Approved for use through 7/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
on Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

					Complete if Known	
Substitute	e for form	1449B/PTO		Application Number	09/831,047	
INF	ORMA	TION	DISCLOSURE	Filing Date	May 3, 2001	
			APPLICANT	First Named Inventor	Blaszczyk-Thurin	
0.7				Group Art Unit	1653	
	(Use as ma	anv sheets a	s necessary)	Examiner Name	S. Snedden	
Sheet	3	of	4	Attorney Docket Number	WST93AUSA	

		NONPATENT LITERATURE DOCUMENTS	_
Examiner Initials*	Cite No.1	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	CY	HANSSON et al. "Mouse monoclonal antibodies against human cancer cell lines with	}
//		specificities for blood group and related antigens. Characterization by antibody binding	
	}	to glycosphingolipids in a chromatogram binding assay", J. Biol. Chem. April 10, 1983	
		258(7):4091-4097	
1	CZ	HOESS et al., "Identification of a peptide which binds to the carbohydrate-specific	
		monoclonal antibody B3". Gene June 15, 1993 128(1):43-49	
	CCR	KAIR et al. "Topological analysis of the functional mimicry between a peptide and a	
		carbohydrate mojety". J. Biol. Chem. February 28, 1997 272(9):5539-5543	
	CCS	MAGNANI et al., "A monosialoganglioside is a monoclonal antibody-defined antigen	
		of colon carcinoma" Science April 3, 1981 212(4490):55-56	<u> </u>
	CCT	MARTENS et al., "Peptides which bind to E-selectin and block neutrophil adhesion", J.	
		Riol Cham Sentember 8, 1995 270(36):21129-21136	
	CCU	MIRALL et al. "Molecular recognition of a peptide mimic of the Lewis Y antigen by	
		an anti-I ewis V antibody" J. Mol. Recog. November-December 1997 10(0):209-270	
	CCV	PASTAN et al., "Characterization of monoclonal antibodies B1 and B3 that react with	
· /		mucinous adenocarcinomas", Cancer Res. July 15, 1991 51(14):3781-3787	
1	CCW	RAO et al., "Sialyl Lewis X mimics derived from a pharmacophore search are selectin	
·		inhibitors with anti-inflammatory activity", J. Biol. Chem. August 5, 1994	i
		269(31):19663-19666	
7	CCX	RODECK et al., "A mucin containing the X, Y, and H type 2 carbohydrate determinants	
$ \supset \rangle$		is shed by carcinoma cells", Hybridgma August 1987 6(4):389-401	
			1

Examiner Signature

Date
Considered

7/2/04

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

¹ Applicant's unique citation designation is attached.

¹ Applicant's unique citation is attached.

¹ Applicant's unique citation designation designation is attached.

¹ Applicant's unique citation designation designati



PTO/SB/08B (08-03)

Approved for use through 7/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

					Complete if Known	
Substitute	e for form 1	449B/PTO		Application Number	09/831,047	
TNE	ORMA'	TION	DISCLOSURE	Filing Date	May 3, 2001	
STATEMENT BY APPLICANT				First Named Inventor	Blaszczyk-Thurin	
317				Group Art Unit	1653	
	(Use as ma	nv sheets a	s necessary)	Examiner Name	S. Snedden	
Sheet	4	of	4	Attorney Docket Number	WST93AUSA	
				ATENT LITERATURE DOCUM		
		Include	the name of the author	(in CAPITAL LETTERS), title	of the article (when appropriate), title of the	

		NONPATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
55	CCY	STAITE et al., "Inhibition of delayed-type contact hypersensitivity in mice deficient in both E-selectin and P-selectin". Blood October 15, 1996 88(8):2973-2979	
55	CCZ	STEPLEWSKI et al., "Isolation and characterization of anti-monosialoganglioside monoclonal antibody 19-9 class-switch variants", <i>Proc. Natl. Acad. Sci. USA</i> December 1985 82(24):8653-8657	
55	DR	BLASZCZYK-THURIN et al., "Molecular recognition of the Lewis Y antigen by monoclonal antibodies", <i>Protein Eng.</i> May 1996 9(5):447-459	
	<u> </u>		
Examiner Signa	iture	Date Considered 9/2/04	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.